EarningsEsperion announced 2Q24 financial results, posting EPS of ($0.33), compared to our estimate of ($0.19), and consensus of ($0.17).
Market CompetitionMerck’s oral PCSK9i and New Amsterdam’s obicetrapib boast greater LDL-C lowering abilities, prompting experts to believe both will be favored if available.
Sales PerformanceNexletol/Nexlizet's 2Q24 sales of $28.3MM came in below the Street's $32.8MM as the growth inflection is taking more time than expected to materialize.